Board Change • May 20
Less than half of directors are independent Following the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 5 non-independent directors. Independent Director SK. Rahman was the last independent director to join the board, commencing their role in 2023. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. 공시 • Apr 27
Techno Drugs Ltd. to Report Q3, 2026 Results on Apr 29, 2026 Techno Drugs Ltd. announced that they will report Q3, 2026 results on Apr 29, 2026 공시 • Jan 29
Techno Drugs Ltd. to Report Q2, 2026 Results on Jan 31, 2026 Techno Drugs Ltd. announced that they will report Q2, 2026 results on Jan 31, 2026 공시 • Nov 09
Techno Drugs Ltd. to Report Q1, 2026 Results on Nov 13, 2025 Techno Drugs Ltd. announced that they will report Q1, 2026 results on Nov 13, 2025 공시 • Oct 30
Techno Drugs Ltd. announces Annual dividend, payable on January 25, 2026 Techno Drugs Ltd. announced Annual dividend of BDT 1.0000 per share payable on January 25, 2026, ex-date on November 20, 2025 and record date on November 19, 2025. 공시 • Oct 29
Techno Drugs Ltd., Annual General Meeting, Dec 24, 2025 Techno Drugs Ltd., Annual General Meeting, Dec 24, 2025, at 10:00 Central Asia Standard Time. Location: hybrid system in combination of physical, presence at institution of diploma engineers, l60/a, kakrail vip road, through the link., Bangladesh 공시 • Oct 21
Techno Drugs Ltd. to Report Fiscal Year 2025 Results on Oct 28, 2025 Techno Drugs Ltd. announced that they will report fiscal year 2025 results on Oct 28, 2025 공시 • Apr 23
Techno Drugs Ltd. to Report Q3, 2025 Results on Apr 29, 2025 Techno Drugs Ltd. announced that they will report Q3, 2025 results on Apr 29, 2025 공시 • Jan 27
Techno Drugs Ltd. to Report Q2, 2025 Results on Jan 30, 2025 Techno Drugs Ltd. announced that they will report Q2, 2025 results on Jan 30, 2025 공시 • Nov 11
Techno Drugs Ltd. to Report Q1, 2025 Results on Nov 14, 2024 Techno Drugs Ltd. announced that they will report Q1, 2025 results on Nov 14, 2024 공시 • Oct 29
Techno Drugs Ltd. Recommends 12% Cash Dividend for the year ended June 30, 2024 The Board of Directors of Techno Drugs Ltd. recommended 12% Cash Dividend only for general shareholders other than Board of Directors for the year ended June 30, 2024. Directors/sponsor are holding 82,776,200 shares and General Public are holding 49,221,988 shares. Cash dividend payable to General Public is Tk. 59,066,386.00. Date of AGM: December 26, 2024. Valuation Update With 7 Day Price Move • Oct 24
Investor sentiment deteriorates as stock falls 17% After last week's 17% share price decline to ৳38.00, the stock trades at a trailing P/E ratio of 25.3x. Average trailing P/E is 18x in the Pharmaceuticals industry in Bangladesh. 공시 • Oct 22
Techno Drugs Ltd. to Report Fiscal Year 2024 Results on Oct 27, 2024 Techno Drugs Ltd. announced that they will report fiscal year 2024 results on Oct 27, 2024 New Risk • Sep 27
New major risk - Financial data availability The company's latest financial reports are more than a year old. Last reported fiscal period ended June 2023. This is considered a major risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. In the worst case scenario, it may be facing other major going concern issues jeopardizing its viability as a listed company. Currently, the following risks have been identified for the company: Major Risks Latest financial reports are more than 1 year old (reported June 2023 fiscal period end). Interest payments are not well covered by earnings (2.0x net interest cover). Share price has been highly volatile over the past 3 months (12% average weekly change). Revenue has declined by 46% over the past year. Minor Risk Market cap is less than US$100m (৳5.87b market cap, or US$49.0m). Valuation Update With 7 Day Price Move • Sep 08
Investor sentiment deteriorates as stock falls 19% After last week's 19% share price decline to ৳40.50, the stock trades at a trailing P/E ratio of 27x. Average trailing P/E is 24x in the Pharmaceuticals industry in Bangladesh. Board Change • Jul 14
Less than half of directors are independent Following the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 5 non-independent directors. Independent Director SK. Rahman was the last independent director to join the board, commencing their role in 2023. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.